AM1 Stock Overview
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 1/6 |
| Dividends | 5/6 |
Amgen Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$258.08 |
| 52 Week High | US$0 |
| 52 Week Low | US$0 |
| Beta | 0.59 |
| 1 Month Change | -0.47% |
| 3 Month Change | -13.51% |
| 1 Year Change | 23.66% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -5.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| AM1 | BG Biotechs | BG Market | |
|---|---|---|---|
| 7D | 2.1% | 0% | 0% |
| 1Y | 23.7% | 0% | 0% |
Return vs Industry: AM1 exceeded the BG Biotechs industry which returned -10.3% over the past year.
Return vs Market: AM1 exceeded the BG Market which returned 17.1% over the past year.
Price Volatility
| AM1 volatility | |
|---|---|
| AM1 Average Weekly Movement | 3.4% |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in BG Market | 0% |
| 10% least volatile stocks in BG Market | 0% |
Stable Share Price: AM1 has not had significant price volatility in the past 3 months.
Volatility Over Time: AM1's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 26,700 | Bob Bradway | www.amgen.com |
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI.
Amgen Inc. Fundamentals Summary
| AM1 fundamental statistics | |
|---|---|
| Market cap | €138.69b |
| Earnings (TTM) | €6.26b |
| Revenue (TTM) | €26.28b |
22.2x
P/E Ratio5.3x
P/S RatioIs AM1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AM1 income statement (TTM) | |
|---|---|
| Revenue | US$28.19b |
| Cost of Revenue | US$8.42b |
| Gross Profit | US$19.78b |
| Other Expenses | US$13.06b |
| Earnings | US$6.72b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 12.52 |
| Gross Margin | 70.15% |
| Net Profit Margin | 23.83% |
| Debt/Equity Ratio | 1,036.8% |
How did AM1 perform over the long term?
See historical performance and comparison